Style | Citing Format |
---|---|
MLA | Ghaemi F, et al.. "Apoa1/Hdl-C Ratio As a Predictor for Coronary Artery Disease in Patients With Type 2 Diabetes: A Matched Case-Control Study." BMC Cardiovascular Disorders, vol. 24, no. 1, 2024, pp. -. |
APA | Ghaemi F, Rabizadeh S, Yadegar A, Mohammadi F, Asadigandomani H, Bafrani MA, Reyhan SK, Esteghamati A, Nakhjavani M (2024). Apoa1/Hdl-C Ratio As a Predictor for Coronary Artery Disease in Patients With Type 2 Diabetes: A Matched Case-Control Study. BMC Cardiovascular Disorders, 24(1), -. |
Chicago | Ghaemi F, Rabizadeh S, Yadegar A, Mohammadi F, Asadigandomani H, Bafrani MA, Reyhan SK, Esteghamati A, Nakhjavani M. "Apoa1/Hdl-C Ratio As a Predictor for Coronary Artery Disease in Patients With Type 2 Diabetes: A Matched Case-Control Study." BMC Cardiovascular Disorders 24, no. 1 (2024): -. |
Harvard | Ghaemi F et al. (2024) 'Apoa1/Hdl-C Ratio As a Predictor for Coronary Artery Disease in Patients With Type 2 Diabetes: A Matched Case-Control Study', BMC Cardiovascular Disorders, 24(1), pp. -. |
Vancouver | Ghaemi F, Rabizadeh S, Yadegar A, Mohammadi F, Asadigandomani H, Bafrani MA, et al.. Apoa1/Hdl-C Ratio As a Predictor for Coronary Artery Disease in Patients With Type 2 Diabetes: A Matched Case-Control Study. BMC Cardiovascular Disorders. 2024;24(1):-. |
BibTex | @article{ author = {Ghaemi F and Rabizadeh S and Yadegar A and Mohammadi F and Asadigandomani H and Bafrani MA and Reyhan SK and Esteghamati A and Nakhjavani M}, title = {Apoa1/Hdl-C Ratio As a Predictor for Coronary Artery Disease in Patients With Type 2 Diabetes: A Matched Case-Control Study}, journal = {BMC Cardiovascular Disorders}, volume = {24}, number = {1}, pages = {-}, year = {2024} } |
RIS | TY - JOUR AU - Ghaemi F AU - Rabizadeh S AU - Yadegar A AU - Mohammadi F AU - Asadigandomani H AU - Bafrani MA AU - Reyhan SK AU - Esteghamati A AU - Nakhjavani M TI - Apoa1/Hdl-C Ratio As a Predictor for Coronary Artery Disease in Patients With Type 2 Diabetes: A Matched Case-Control Study JO - BMC Cardiovascular Disorders VL - 24 IS - 1 SP - EP - PY - 2024 ER - |